ViiV opens up brand-new HIV med Tivicay for cheap copies in poor countries

HIV drug specialist ViiV Healthcare has tossed a brand-new product into the Medicines Patent Pool. ViiV--a joint venture of GlaxoSmithKline ($GSK), Pfizer ($PFE) and Shionogi--inked a deal with MPP to speed access to cheap copies of Tivicay (dolutegravir) in developing countries. Among the pricier HIV treatments, Tivicay was FDA-approved last year, and analysts figure it could hit $5 billion in sales. Report

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.